ASAkash Singh

Akash Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akash Singh has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CTNNB1 Mutational Profile with Clinico-pathological Parameters of Indian Patients with Desmoid-Type Fibromatosis: A Retrospective Study

    by Akash Singh, Kinjal Singh, Sameer Rastogi, Pratibha Amare, Adarsh Barwad, Asit Ranjan, Simran Kaur, Stanzin Spalkit

    Desmoid-type fibromatosis (DTF) is a rare mesenchymal tumor characterized by high local recurrence and no metastatic potential, with sporadic cases often linked to CTNNB1 gene mutations. While global studies have detailed the frequency and prognostic significance of these mutations, there remains a significant lack of large-scale mutational profiling data from the Indian subcontinent. This study aims to address this knowledge gap by providing the first molecular description of CTNNB1 mutational subtypes in an Indian DTF patient population. The aim of the study is to characterize the CTNNB1 exon-3 mutational profile in Indian patients with DTF and to evaluate its association with key clinicopathological features and treatment outcomes. This retrospective analysis included formalin-fixed paraffin-embedded (FFPE) tissue blocks from 38 histopathologically confirmed DTF patients treated at a single tertiary center in India between January 2021 to April 2025. DNA was extracted from each of these patients, and exon-3 of the CTNNB1 gene was amplified using polymerase chain reaction, followed by bidirectional sequencing for mutation identification. Histopathological diagnoses were independently validated by two sarcoma pathology experts. Clinical data, including demographics, tumor characteristics, and treatment outcomes, were collected from medical records. The cohort included 38 patients (24 women, 14 men; median age 29.5 years, range 7–59). CTNNB1 mutations were present in 23 patients (60.5%). Extremities (36.8%) and the abdomen (34.2%) were the most common tumor sites, with a median baseline tumor diameter of 7.95 cm. Among mutation-positive cases, T41A was most frequent (60.9%), followed by S45F (30.4%) and S45P (8.7%). Fifteen patients (39.5%) had CTNNB1 wild-type tumors. Surgery was the most common initial treatment (15/38). Recurrence occurred in 17 of 29 surgically treated patients (58.6%), including 5 of 7 (71.4%) with S45F mutations. In later treatment lines, active surveillance (50%) and sorafenib (42.1%) predominated. Overall, 26 patients (68.4%) achieved disease control. This study offers initial insights into CTNNB1 mutations in Indian DTF patients, revealing a higher frequency of the wild-type gene compared with international data. This finding suggests potential regional differences in disease characteristics. Therefore, further extensive, multi-center studies with long-term follow-up are essential to fully understand DTF in the Indian population, which will be crucial for developing more precise diagnostic methods and effective treatment strategies tailored to this specific demographic.

  • Radiation-Associated Sarcoma in a Resource-Constrained Setting: A Decade of Real-World Outcomes From a Tertiary Care Sarcoma Center in India

    by Varun Sheoran, Sorun Shishak, Kinjal Singh, Sameer Rastogi, Aryan Maheshwari, Rambha Pandey, Shamim A. Shamim, Adarsh Barwad, Yamini Dharmashaktu, Ekta Dhamija, et al.

    PURPOSE: Radiation-associated sarcomas (RAS) are rare tumors developing in previously irradiated areas. Most data come from high-income countries, with limited reports from low- and middle-income countries (LMICs). To our knowledge, this is the largest RAS cohort from India, examining clinical features, genetic predisposition, systemic therapies, and outcomes, in a resource-limited setting. MATERIALS AND METHODS: We conducted a retrospective analysis of a sarcoma database at AIIMS, New Delhi, from January 2015 to June 2025. Patients ≥18 year with biopsy-confirmed RAS, meeting modified Cahan criteria, were included. RESULTS: Twenty-three patients (0.32% of 7,138 sarcoma cases evaluated) were diagnosed with RAS. The median age at diagnosis was 51.1 years, with a median latency of 13.25 years following radiotherapy. Breast cancer was the most common antecedent malignancy (21.7%). Soft tissue sarcomas were predominant (14, 60.9%), with undifferentiated pleomorphic sarcoma (8, 34.8%) being the most frequent histologic subtype. At presentation, 12 patients (52.2%) had metastatic disease, while three (13.1%) had locally unresectable tumors. The majority of tumors were high-grade (20, 87.0%), with a median tumor size of 6.9 cm. Among eight patients with resectable disease, seven underwent surgery, achieving R0 resection in 62.5% of cases. Re-irradiation was performed in three patients (13.0%). Sixteen patients (69.6%) received systemic therapy: 12.5% had partial response, 25% had stable disease, and two patients on immunotherapy had progressive disease. At a median follow-up of 68.2 months, the median overall survival was 59.2 months and 13.4 months for patients with nonmetastatic and metastatic disease, respectively. CONCLUSION: Despite large, high-grade, and advanced tumors, curative surgery was feasible in most nonmetastatic cases, and systemic therapies were widely used. The favorable survival outcomes underscore the importance of centralized, multidisciplinary sarcoma care in LMICs. Lack of immunotherapy responses calls for investigation into resistance mechanisms and histology-specific treatments.

  • Top Cited Papers

    Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow

    by Nihanthy D. Sreenath, Kinjal Singh, Sameer Rastogi, Niranjan Biswal, Akash Singh, Adarsh Barwad, Asit Ranjan Mridha, Shivanand Gamanagatti, Shamim Ahmed Shamim, Yamini Dharmashaktu, et al.

    PURPOSE: Sarcomas exhibit clinicopathologic heterogeneity, leading to diagnostic and therapeutic uncertainty. This study assesses the clinical value of integrating targeted RNA-based next-generation sequencing (NGS) into a multidisciplinary sarcoma workflow to improve diagnosis, enable comprehensive molecular characterization, and inform personalized treatment strategies. METHODS: In this prospective single-center study, 68 patients with suspected or confirmed soft tissue sarcoma underwent RNA-based NGS using a 138-gene fusion panel, integrated within a multidisciplinary sarcoma framework. Genomic findings integrated with histopathology and immunohistochemistry for diagnostic reclassification and treatment changes. RESULTS: Of 70 patients advised RNA-based NGS, 68 (97.1%) were evaluable (median age, 38.5 years). Soft tissue sarcomas predominated (77.1%), with 67.1% presenting with advanced disease. Initial histology included 17 round cell sarcomas (RC), 19 undifferentiated sarcomas (US), and 34 other subtypes. Among evaluable RC cases (n = 16), NGS identified diagnostic fusions in 87.5%, enabling reclassification in 68.7% and treatment change in 18.7%. In US, fusions were detected in 21.1%, all reclassified, with treatment altered in 75%. In other subtypes, fusions were found in 48.4%, enabling reclassification in 39.3% and treatment impact in 21.2%. Nondiagnostic mutations (eg, TP53 , SLX4 , NF1 ) were observed in 47.4% of US and 18.2% of other subtypes. Potentially actionable variants ( KIT , PIK3CA ) were seen in 5.8%. Overall, RNA-NGS was clinically informative in 50%, refined diagnosis in 41.1%, and influenced treatment in 26.4% of patients. CONCLUSION: To our knowledge, this first-of-its-kind study highlights the clinical utility of integrating targeted RNA-based NGS into multidisciplinary sarcoma care, enabling diagnostic reclassification in 41.1% of cases most notably in round cell sarcomas with atypical morphology. Both canonical and rare fusions informed individualized therapy, reinforcing RNA-NGS as a pivotal tool for diagnostic refinement and precision oncology in sarcoma management.